Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has received an average rating of "Buy" from the eight analysts that are presently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $10.57.

A number of research analysts have recently issued reports on AQST shares. Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $17.00 price objective for the company. Lake Street Capital reduced their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD lifted its position in shares of Aquestive Therapeutics by 16.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company's stock valued at $99,000 after acquiring an additional 3,821 shares during the period. MetLife Investment Management LLC increased its stake in Aquestive Therapeutics by 11.4% in the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company's stock valued at $143,000 after purchasing an additional 4,125 shares in the last quarter. Bank of Montreal Can raised its holdings in Aquestive Therapeutics by 10.1% during the fourth quarter. Bank of Montreal Can now owns 54,300 shares of the company's stock worth $193,000 after purchasing an additional 4,999 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Aquestive Therapeutics by 3.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company's stock worth $750,000 after purchasing an additional 7,129 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in Aquestive Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company's stock valued at $117,000 after purchasing an additional 7,347 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock traded down $0.17 during midday trading on Monday, hitting $2.87. 1,254,590 shares of the company's stock were exchanged, compared to its average volume of 1,597,580. The stock has a market cap of $283.76 million, a price-to-earnings ratio of -6.38 and a beta of 2.59. Aquestive Therapeutics has a 12-month low of $2.24 and a 12-month high of $5.80. The firm's 50 day simple moving average is $2.97 and its 200 day simple moving average is $3.90.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. On average, equities research analysts forecast that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.